Finepoint Capital LP
- SEC CIK
- 0001608126
- Latest filing
- Aug 13, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 13, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 24
- −1 vs. Q2 2024
- Portfolio value
- $822.3M
- +$470.1M (+133.4%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| QXOQXO, Inc. | COM NEW | 25,750,781 | $406.1M | 49.4% | +25,750,781 | New | History |
| LBRDKLiberty Broadband Corp | COM SER C | 1,994,510 | $154.2M | 18.7% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 731,960 | $33.2M | 4.0% | +2,496+0.3% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 54,428 | $29.5M | 3.6% | +400+0.7% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 190,072 | $28.4M | 3.5% | +800+0.4% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,782,267 | $24.9M | 3.0% | +5,539+0.3% | Added | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 650,852 | $20.9M | 2.5% | +12,500+2.0% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 388,835 | $19.6M | 2.4% | 00.0% | Unchanged | History |
| SRPTSarepta Therapeutics, Inc. | COM | 133,535 | $16.7M | 2.0% | +700+0.5% | Added | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 557,762 | $16.1M | 2.0% | +15,000+2.8% | Added | History |
| ARVNArvinas, Inc. | COM | 574,378 | $14.1M | 1.7% | 00.0% | Unchanged | History |
| ACADAcadia Pharmaceuticals Inc | COM | 905,384 | $13.9M | 1.7% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 256,449 | $13.5M | 1.6% | 00.0% | Unchanged | History |
| RLAYRelay Therapeutics, Inc. | COM | 1,626,146 | $11.5M | 1.4% | +20,800+1.3% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 433,471 | $7.25M | 0.9% | 00.0% | Unchanged | History |
| SLDBSolid Biosciences Inc. | COM NEW | 961,251 | $6.70M | 0.8% | 00.0% | Unchanged | History |
| EYPTEyePoint, Inc. | COM NEW | 707,404 | $5.65M | 0.7% | 00.0% | Unchanged | History |
| Swiftmerge Acquisition CorpG63836111 | *W EXP 12/13/202 | 490,000 | $39.2K | <0.1% | 00.0% | Unchanged | – |
| Compass Digital Acquisitn CoG2476C123 | *W EXP 09/29/202 | 459,906 | $28.1K | <0.1% | 00.0% | Unchanged | – |
| MNYWWMoneyHero Ltd | *W EXP 09/13/202 | 895,000 | $26.9K | <0.1% | 00.0% | Unchanged | History |
| Marblegate Acquisition Corp.56608A113 | *W EXP 08/31/202 | 735,000 | $25.3K | <0.1% | 00.0% | Unchanged | – |
| Ys Biopharma Co LtdG9845F117 | *W EXP 03/15/202 | 489,999 | $24.2K | <0.1% | 00.0% | Unchanged | – |
| CLDICalidi Biotherapeutics, Inc. | COM | 12,500 | $14.2K | <0.1% | 00.0% | UnchangedConverted for a 1-for-10 split | History |
| CLDWWCalidi Biotherapeutics, Inc. | *W EXP 03/14/202 | 655,200 | $8.58K | <0.1% | 00.0% | Unchanged | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | $318.4M | – |
| iShares Russell 2000 ETF464287655 | ETF | $235.2M | – |
Sold out since Q2 2024 (2)
Positions held at the end of Q2 2024 that are gone from this filing.